Correction notice regarding the H1 2025 report and the corresponding press release dated September 30, 2025, 00:18 a.m.
Biofrontera AG issued a correction notice regarding its H1 2025 report and a press release dated September 30, 2025. The correction addresses typing errors in the "Outlook and Forecast" sections of both the German and English versions of the report. The corrected EBITDA forecast for 2025 is now EUR 1.5 to 3.5 million, up from the previously stated EUR 0.5 to 1.5 million. Additionally, cash and cash equivalents as of December 31, 2025, are corrected to EUR 1 to 3 million, from EUR 0.5 to 3 million. The updated report is available on the company's website.
Biofrontera AG
by Investor Relations
Business news for the stock market
Biofrontera AG: Correction notice regarding the H1 2025 report and the corresponding press release dated September 30, 2025, 00:18 a.m.
Leverkusen (pta000/30.09.2025/22:48 UTC+2)
"Reference document: Half-year financial report as of June 30, 2025 (German and English versions), published on September 30, 2025
Reason for correction:
Correction of contradictory information regarding the forecast due to typing errors
Affected text passages
Section "Outlook and Forecast" (German version): Table "Geänderte Prognose 2025" at the bottom of page 22 and the paragraph immediately below it
Section "Outlook and Forecast" (English version): Table "Revised forecast 2025" at the bottom of page 21 and the paragraph immediately below it
Corrected information (consistent with the forecast in the ad hoc announcement dated August 1, 2025)
EBITDA 2025: • Correct: EUR 1.5 to 3.5 million • Originally incorrectly stated: EUR 0.5 to 1.5 million
Cash and cash equivalents as of December 31, 2025: • Correct: EUR 1 to 3 million • Originally incorrectly stated: EUR 0.5 to 3 million
The corrected half-year financial report is available on the company's website.
The corresponding press release dated September 30, 2025, 00:18 a.m., which was equally incorrect, was corrected on September 30, 2025, 8:15 p.m.
The
Management Board"
(end)
| Emitter: | Biofrontera AGHemmelrather Weg 20151377 LeverkusenGermany | |
|---|---|---|
| Contact Person: | Investor Relations | |
| Phone: | +49 (0) 214 87 63 20 | |
| E-Mail: | ir@biofrontera.com | |
| Website: | www.biofrontera.com | |
| ISIN(s): | DE000A4BGGM7 (Share) | |
| Stock Exchange(s): | Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate |
[ source: https://www.pressetext.com/news/1759265280264 ]
(c) pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext. Archive: https://www.pressetext.com/channel/Adhoc The emitter is responsible for the content. Contact: adhoc@pressetext.com or +43-1-81140-0.
